Benefits exceed risks of newer antidepressant medications in youth--maybe not.
Potter
W Z
WZ
Translational Neuroscience, Merck Research Laboratories, North Wales, Pennsylvania, USA. william_potter@merck.com
D000293:Adolescent; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy*; D018570:Risk Assessment; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D013405:Suicide
D018687:Antidepressive Agents, Second-Generation; D017367:Selective Serotonin Reuptake Inhibitors